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314 The Journal of Thoracic and CardioObjective: We aimed to develop multivariable models of preoperative risk factors
that predict long-term survival after coronary artery bypass grafting in patients with
ejection fraction 25% or less.
Methods: We retrospectively evaluated 544 consecutive patients with ejection
fraction 25% or less who underwent coronary artery bypass grafting from 1992 to
2002 at a single institution. Long-term survival data (mean follow-up 4.1 years)
were obtained from the National Death Index. Multivariable Cox regression analysis
was performed to construct a predictive score for long-term mortality. A split-
sample approach was also used building a model on a training group (n 360); this
model was then tested on a separate validation group (n  184).
Results: From the entire database, the predictive score was calculated according to
the following equation: 0.430(if past congestive heart failure) 0.049(age in years)
 0.507(if peripheral vascular disease) 0.580(if emergency operation) 0.366(if
chronic obstructive pulmonary disease). The 5-year survivals of the predictive score
quartiles were 82.3%, 78.2%, 65.5%, and 45.5% (P  .0001). The model based on
the training group had four independent predictors for long-term mortality (the same
as the listed equation except for past congestive heart failure). The 5-year survival
rates of the quartiles were 90.1%, 75.4%, 64.3%, and 49.2% in the training group
(P  .0001) and 77.4%, 71.2%, 65.8%, and 45.5% in the validation group (P 
.0001).
Conclusion: Coronary artery bypass grafting in patients with severe ischemic
cardiomyopathy achieves satisfactory midterm and long-term survival in selected
patients. This new score, which is based on long-term data from a large number of
patients, may aid clinicians in selecting therapeutic interventions for patients with
ischemic cardiomyopathy.
Congestive heart failure (CHF) affects more than 5 million Ameri-cans and contributes to a growing number of hospital admissions.1The most common cause of CHF worldwide is coronary arterydisease.2 Left ventricular dysfunction of ischemic etiology is asso-ciated with approximate 5-year survivals of 40% with medicaltreatment and 60% with coronary artery bypass grafting (CABG).3
Multiple therapeutic options for patients with low left ventricular ejection fraction
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CD(EF) are available, including medical therapy, CABG,
biventricular pacing, ventricular-assist devices and ortho-
topic heart transplantation.3-7 Selecting between CABG and
other interventions is difficult, and the choice would be
facilitated if prognostic factors for long-term outcomes were
known. It has been shown in multiple studies that CABG
results in considerable improvement in long-term survival,
as well as quantitative improvements in EF and symptom-
atic New York Heart Association (NYHA) class.8-14 How-
ever, there is no full consensus on exactly which patients
have the greatest potential for long-term survival.
Multiple preoperative risk factors have been associated
in previous studies with decreased survival benefit. These
include age at the time of surgery, female sex, emergency
status, end-systolic volume index, number of previous myo-
cardial infarctions, the quality of coronary arteries, com-
plete revascularization, myocardial viability, left ventricular
end diastolic pressure, and NYHA functional class IV sta-
tus.8,11,12,14-19 These various risk factors may increase mor-
tality to a point that outweighs any potential long-term
benefits of revascularization. In this study, we used long-
term follow-up data of 544 consecutive patients with low
EF (25%) to create a preoperative score that can be used
in predicting long-term CABG risk for death and assist in
determining therapy for patients with a markedly low EF
and coronary artery disease.
Materials and Methods
Patient Population and Data
Our study consisted of 544 consecutive patients with low EF
(25%), who underwent isolated CABG between January 1992
and March 2002 at the St. Luke’s–Roosevelt Hospital Center
affiliated with Columbia University College of Physicians and
Surgeons in New York. Patients who underwent concomitant valve
surgery or aneurysmectomy were excluded from the study. Indi-
cations for CABG were based on standard clinical and angio-
graphic criteria. Complete revascularization was the policy of our
institution, and reliance on echocardiography, particularly trans-
esophageal echocardiography, in addition to anatomy determined
the number of anastomoses. Moving and thick segments indicating
myocardial viability were all revascularized.
Data were prospectively collected during admission as part of
routine clinical practice and entered into the New York State adult
cardiac surgery report for the variables shown in Tables 1 and 2.
CHF was diagnosed by paroxysmal nocturnal dyspnea or dyspnea
on exertion from heart failure or chest radiograph showing pul-
monary congestion. CHF was characterized as current when diag-
nosed within 2 weeks before the procedure or past when diagnosed
between 2 weeks to 6 months before the procedure. Peripheral
vascular disease (PVD) was diagnosed by one of the following
criteria: (1) a history of stroke with or without residual deficit; (2)
angiographic or ultrasonographic demonstration of at least 50%
narrowing in a major cerebral or carotid artery (common or inter-
nal) and history of nonembolic stroke or previous surgery for such
disease (a history of bruits or transient ischemic attacks is not
sufficient evidence for carotid or cerebrovascular disease); (3)
The Journal of Thoraciangiographic demonstration of at least 50% narrowing in a major
aortoiliac vessel and previous surgery for such disease, absent
femoral pulses, or inability to insert a catheter or intra-aortic
balloon pump because of iliac aneurysm or obstruction of the
aortoiliac arteries (tortuosity of the vessel alone does not constitute
aortoiliac disease as well as abdominal aortic aneurysm, history of
aortobifemoral bypass, and absence of a femoral pulse on either
TABLE 1. Patient and disease characteristics in patients
with low EF undergoing CABG (<25%, n  544)
Age (y, mean SD) 65.2  10.1
Female (No.) 143 (26.3%)
Race (No.)
White 308 (56.6%)
Black 123 (22.6%)
Other 113 (20.8%)
Vessels involved (No.)
One-vessel disease 10 (1.8%)
Two-vessel disease 89 (16.4%)
Three-vessel disease 445 (81.8%)
Unstable angina (No.) 446 (82.0%)
Canadian Cardiovascular Society angina
class (mean SD)
3.79  0.50
Previous myocardial infarction (No.) 360 (66.2%)
Transmural myocardial infarction (No.) 302 (55.5%)
More previous myocardial infarction (No.) 200 (36.8%)
Urgency of operation (No.)
Emergency 91 (16.7%)
Urgent 345 (63.4%)
Elective 108 (19.9%)
Previous cardiac operation (No.) 40 (7.4%)
Previous percutaneous coronary
intervention (No.)
51 (9.4%)
Ejection fraction (%, mean SD) 18.6  6.4
Hemodynamic instability (No.) 37 (6.8%)
Shock (No.) 9 (1.7%)
Nitroglycerin 24 h before operation (No.) 144 (26.5%)
Thrombolysis (No.) 40 (7.4%)
Myocardial rupture (No.) 1 (0.2%)
Current CHF (No.) 250 (46.0%)
Past CHF (No.) 149 (27.4%)
PVD (No.) 147 (27.0%)
Body mass index (kg/m2, mean  SD) 21.3  4.5
Hypertension (No.) 383 (70.4%)
Left ventricular hypertrophy (No.) 168 (30.9%)
COPD (No.) 122 (22.4%)
Preoperative intra-aortic balloon pump (No.) 104 (19.1%)
Diabetes mellitus (No.) 248 (45.6%)
Calcified aorta (No.) 77 (14.2%)
Hepatic failure (No.) 2 (0.4%)
Renal failure (No.) 22 (4.0%)
Dialysis (No.) 16 (2.9%)
Immune deficiency (No.) 4 (0.7%)
Smoking past 2 wk (No.) 109 (20.0%)
Smoking past 1 y (No.) 87 (16.0%)right or left); and (4) angiographic demonstration of at least 50%
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surgery for such disease, absent pedal pulses, or inability to insert
a catheter or intra-aortic balloon pump because of obstruction in
the femoral arteries (both dorsalis pedis and posterior tibial need to
be absent in one foot; a negative popliteal pulse alone does not
constitute femoral or popliteal disease as well as medications for
PVD without indication of femoral or popliteal disease). Chronic
obstructive pulmonary disease (COPD) was diagnosed by one of
the following criteria: (1) chronic bronchodilator therapy to avoid
disability from obstructive airway disease longer than 3 months,
(2) a forced expiratory volume in 1 second less than 75% of the
predicted value or less than 1.25 L, and (3) a room air PaO2 less
than 60 mm Hg or PaCO2 greater than 50 mm Hg. Preoperative
risk stratification was performed according to the EuroSCORE
model.20
Data Analysis
Long-term patient mortality data were obtained from the United
States Social Security Death Index database (http://ssdi.genealo-
gy.rootsweb.com). The sensitivity of the National Death Index to
identify deaths is between 92% and 99%, depending on which
identifiers are available.21 Social Security number alone has the
best accuracy of any combination of other identifiers (first initial,
last name day of birth, month of birth, year of birth, etc), with a
sensitivity of 97% and a specificity of 99%.21 In this study we used
only Social Security numbers, which were available for most
patients (98.7%); this allowed us to avoid the use of patients’
names. Moreover, patients without a Social Security number (n 
7) were censored at the time of discharge from the hospital. The
index was queried in September 2002, and patients not found in the
TABLE 2. Intraoperative characteristics, early mortality,
length of stay and major complication after CABG in pa-
tients with low EF (<25%, n  544)
Intraoperative characteristics
Two or more arterial grafts (No.) 259 (47.6%)
Number of distal anastomoses (mean SD) 3.4  0.9
OPCAB (No.) 82 (15.1%)
Microscope use (No.) 234 (43.0%)
Early mortality and length of stay
EuroSCORE standard (mean SD) 8.25  2.82
30-d mortality (No.) 30 (5.5%)
In-hospital death (No.) 33 (6.1%)
Stay (d, mean SD) 13  11.3
Major complications
Intraoperative stroke (No.) 25 (4.6%)
Over 24 h stroke (No.) 4 (0.7%)
Postoperative myocardial infarction (No.) 5 (0.9%)
Deep sternal wound infection (No.) 9 (1.7%)
Bleeding/reoperation (No.) 14 (2.6%)
Sepsis/endocarditis (No.) 7 (1.3%)
Gastrointestinal bleeding, perforation,
or infarction (No.)
12 (2.2%)
Renal failure/dialysis (No.) 11 (2.0%)
Respiratory failure (No.) 42 (7.7%)index were assumed to be alive at that date.
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Numerica variables are presented as mean  SD, whereas discrete
variables were summarized by percentages. Multivariable Cox
proportional hazard regression models22 were used to reveal the
statistically significant risk factors that were associated with long-
term mortality. Hazard ratios (HRs) and 95% confidence intervals
were calculated. The model selection was done with backward
stepwise method starting from all variables with P  .05 in
univariate analyses. Interaction terms were considered but were
not important. Continuous variables were checked for conformity
with linear gradient. This multivariable model was then used to
calculate a predictive score for long-term mortality after CABG.
We also used a split-sample approach. The total number of
patients was divided randomly into two groups (training and
validation sets). We built a multivariable model from the data of
the 360 patients in the training set, and we tested the discriminating
performance of the derived model on the remaining 184 patients of
the validation set. The coefficients of the model derived in the full
data set may be inflated because of overfitting; that is, the relative
differences in prognosis between the risk quartiles may be smaller
than suggested by the full data set model. This is not a problem in
the split-sample approach. A measure of the potential shrinkage
that needs to be applied to the coefficients of the full data set model
may be obtained from the shrinkage slope b of a Cox regression
that is modeling (in the validation data set) the relative hazard of
death as a function of the score derived in the training data set.23
We estimated the shrinkage b in our data.
For all models tested, we generated Kaplan-Meier curves24
according to score quartiles, and the four curves were compared
with the log-rank test, with adjustment for trend as appropriate. We
also estimated for each model and data set the extreme quartile
odds ratio (EQuOR)25; that is, the odds of death in the high-risk
quartile divided by the odds of death in the low-risk quartile. The
larger the EQuOR value, the better the discrimination of a model
between high- and low-risk patients. All analyses were performed
with SPSS version 11.0 software (SPSS, Inc, Chicago, Ill), and all
TABLE 3. Potential predictors for long-term mortality in
patients with low EF (<25%) undergoing CABG (univariate
Cox regression analysis)
Variable HR
95% Confidence
interval P value
Age (continuous
variable)
1.053 1.037–1.070 .001
Body mass index
(continuous variable)
1.047 1.016–1.079 .003
Emergency operation 1.83 1.30–2.58 .001
Urgent operation 0.71 0.55–0.97 .003
PVD 1.93 1.44–2.58 .001
COPD 1.53 1.13–2.09 .001
Current CHF 1.40 1.06–1.86 .019
Past CHF 1.50 1.11–2.04 .009
Calcified aorta 1.91 1.36–2.69 .001
Immune deficiency 5.70 1.39–23.31 .016
OPCAB surgery 1.77 1.17–2.67 .007P values are 2-tailed.
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long-term mortality. A, Age. B, PVD. C, Emergency operation. D, COPD. E, Past CHF.
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Clinical Characteristics, Early Outcome, and Long-
Term Survival
Patient and disease characteristics are summarized in Table
1. The mean standard EuroSCORE of the 544 patients was
8.25  2.82. During 2214 patient-years of follow-up (mean
follow-up 4.1  3.1 years), 192 deaths (35.3%) were re-
corded. Table 2 summarizes the procedural data, early mor-
tality, and length of stay, as well as major complications
after CABG, in the study cohort. Thirty-day mortality in this
series of patients with low EF was 5.5%, and 1-, 5-, and
10-year survivals were 85%  2%, 68%  2% and 45% 
4%, respectively. Most patients (81.8%) had three-vessel
disease, and the mean number of anastomoses per patient
was 3.4, indicating a high proportion of complete revascu-
larization. Almost half the patients received two or more
arterial grafts including bilateral internal thoracic arteries,
and almost 1 in 6 patients underwent off-pump CABG
(OPCAB). The 5-year survival in this subgroup of patients
was 45%  4%, versus 70%  2% in the on-pump sub-
group (P0.006); however, patients undergoing OPCAB
had higher EuroSCORE (9.3 vs 8.0, P  .001).
Building a Predictive Score for the Entire Database
The results of univariate Cox regression analysis are shown
in Table 3. In multivariable Cox regression analysis the
retained independent predictors for long-term mortality in
the overall data set, included past CHF (HR 1.54, P .006),
age (HR 1.050 per year, P  .001), PVD (HR 1.66, P 
.001), emergency operation (HR 1.79, P  .001), and
Figure 2. Kaplan-Meier curves of quartiles according to con-
structed HAVOC score of all patients with low EF (<25%) under-
going CABG (n  544).COPD (HR 1.44, P  .021). We called the score derived
318 The Journal of Thoracic and Cardiovascular Surgery ● Febrfrom these factors the HAVOC score. Kaplan-Meier curves
of all 544 patients with low EF stratified according to each
of these independent predictors of long-term mortality are
shown in Figure 1.
The predictive score that was based on these five factors
was calculated according to the following: equation
HAVOC  0.430(if past CHF)  0.049(age in years) 
0.507(if peripheral vascular disease)  0.580(if emergency
operation)  0.366(if COPD). We divided all patients into
quartiles according to HAVOC score, and we estimated the
survival for each quartile as shown in Figure 2. The Kaplan-
Meier curves of the quartiles diverged widely (5-year sur-
vival rates: 82.3%, 78.2%, 65.5%, and 45.5%), and this was
highly statistically significant (log-rank test adjusted for
trend P  .0001). The EQuOR was 6.0. There were also
differences among the quartiles of the HAVOC score in
terms of 30-day mortality: 3.0%, 2.9%, 5.1%, and 10.9%
from low- to high-risk group (P  .011).
Split-Sample Model
Multivariable Cox regression analysis for the training set
retained as independent predictors for long-term mortality
in this group of patients the following variables: age (HR
1.052 per year, P  .001), PVD (HR 1.72, P  .004),
emergency operation (HR 1.90, P  .003), and COPD (HR
1.50, P  .043). We calculated the new score by the
following new equation S  0.051(age in years)  0.543(if
PVD)  0.641(if emergency operation)  0.405(if COPD).
We obtained a shrinkage coefficient of 0.78. The Kaplan-
Meier curves of the quartiles diverged widely in both
groups, as shown in Figure 3, and this was statistically
significant not only in the training set (log-rank test adjusted
for trend P  .0001) but also in the validation group (P 
.0001). The survival rates in the quartiles in the training set
were 90.1%, 75.4%, 64.3%, and 49.2%, and the EQuOR
was 8.4. The survival rates in the validation set were 77.4%,
71.2%, 65.8%, and 45.5%, and the EQuOR in the validation
set was 3.7.
Discussion
This study is one of the largest to examine long-term sur-
vival data and risk factors in patients undergoing CABG for
ischemic cardiomyopathy. On the basis of these data, we
have proposed a predictive score for long-term survival
after CABG in patients with low EF. We determined that
independent preoperative predictors for long-term mortality
included past CHF, age at time of surgery, PVD, emergency
operation, and COPD, which may be summarized as the
mnemonic HAVOC score. We showed for the first time that
COPD and PVD may represent strong predictors for long-
term mortality in patients with low EF undergoing CABG.
The predictive HAVOC score consists of only five factors
and it is easy to calculate, even at bedside.
uary 2005
ients
DeRose et al Surgery for Acquired Cardiovascular Disease
A
CDSeveral previous studies have examined preoperative
risk factors in this population. Age is clearly a predictor of
mortality risk.11,12,15 Several studies have also suggested
that the severity of cardiac dysfunction, as measured by
end-systolic volume index,15 number of previous myocar-
dial infarctions,15 NYHA functional class IV status,8,11-13
and myocardial viability,6,16-18 are important determinants
of death risk. The type of intervention is probably also
important, and previously suggested determinants have in-
cluded the quality of coronary arteries12,16 as well as emer-
gency versus elective status,16 which was also identified as
an independent predictor in our model. Female sex, diabe-
tes, number of diseased vessels, and hypertension have been
proposed in other studies14,19,26 but were not independently
statistically significant in our data set, and they were also
not found to be important in another large study.16
The identification of preoperative risk factors regarding
the long-term mortality after CABG in patients with low EF
is often hampered by limitations in the study designs, inad-
equate sample size or follow-up, and inconsistent defini-
tions of low EF. Almost all the reports in the literature are
retrospective investigations, and the prospective study by
Shah and colleagues19 was limited to 57 patients. Moreover,
these studies differed from our analysis in the preoperative
factors being considered. Most of them did not analyze
other extracardiac factors and comorbidities, such as COPD
and PVD. Such factors were found in our analysis to be
strong independent predictors for long-term mortality, and
they suggest that pulmonary and vascular comorbidities
may have a key impact in determining long-term outcome
Figure 3. Kaplan-Meier curves of quartiles according
set of 360 patients (A) and in validation set of 184 patfor these patients. Finally, there is no consensus in the
The Journal of Thoraciliterature regarding the definition of left ventricular dys-
function. We, along with others,8,26 analyzed patients with
an EF of 25% or less, whereas still others have studied
patients with an EF less than 30%6,13,14,16 or even less than
40%.11,15,19 On the other hand, other groups have used more
strict criteria and analyzed only patients with EF less than
20%.7,9,12 These differences in definitions may affect the
importance of predictive factors.
Previous studies have noted a low rate of coronary re-
vascularization in patients with ischemic cardiomyopathy.
A retrospective study of reversible defects in patients with
ischemic cardiomyopathy at Mayo Clinic revealed a revas-
cularization rate of only 13% through 5 years. This low rate
of revascularization reflects at least in part the absence of
optimal treatment for this complex group of patients and
points to the need for a randomized clinical trial.27 It also
highlights that there is some skepticism regarding proceed-
ing with CABG for these patients because of the uncertainty
about their long-term outcomes. Severe low left ventricular
dysfunction is known to increase morbidity and mortality
after CABG. However, recent retrospective studies have
shown that CABG in patients with an EF less than 30% can
have an acceptable perioperative mortality, ranging from
4% to 11%.8-10,12,14,26 Patients demonstrate improvements
in both left ventricular EF and NYHA functional class after
surgical revascularization in most studies,8-11 and for some
patients long-term survival may be feasible after CABG.
The 5- and 10-year survivals in our study were 68%  2%
and 45%  4%, respectively, well in concordance with
other recent studies in which 5-year survival rates have
nstructed score S (split-sample approach) in training
(B).to coranged from 56% to 72%.8,9,12,14,19,26 However, the patients
c and Cardiovascular Surgery ● Volume 129, Number 2 319
Surgery for Acquired Cardiovascular Disease DeRose et al
A
CDundergoing OPCAB had a significantly lower long-term
survival than those undergoing on-pump CABG. In our
study this undoubtedly was related to selection bias, because
the patients undergoing OPCAB had a significantly higher
mean EuroSCORE. In addition, we have shown that the
detrimental effect of OPCAB on midterm survival changed
during the last 5 years in our institution after innovative
techniques became available.28 The improvement in opera-
tive technique, the current application of robotic techniques,
and the more common use of bilateral internal thoracic
artery grafts may achieve even better survivals without any
increase in operative mortality.5,29,30
Other than CABG, the other major option for therapy in
ischemic cardiomyopathy is orthotopic heart transplanta-
tion. In determining whether a patient is a candidate for
CABG or heart transplantation, a number of factors need to
be considered. Heart transplantation is limited by a severe
shortage of donor organs, considerable expense, moderate
long-term survival, and need for continuous immunosup-
Figure 4. Algorithm for ischemic cardiomyopathy treatment ac-
cording to developed HAVOC score. Patients with HAVOC scores
between 3.60 and 4.05 (quartile above median of our data set) may
be considered for either revascularization or transplantation can-
didacy.pression. However, it has been shown to be beneficial in
320 The Journal of Thoracic and Cardiovascular Surgery ● Febrpatients with NYHA functional class IV symptoms refrac-
tory to medical management who have no other impair-
ments.4 Unfortunately, transplantation remains an option
limited to only a small number of patients.7 With the aging
population, more patients are living well past the traditional
age ceilings for acceptability onto a transplant list. The
HAVOC score developed in this study may serve to guide
physicians in making decisions regarding transplantation
versus CABG. Thus the HAVOC score may be used to
modify and clarify our previously proposed algorithm for
selection of intervention in patients with ischemic cardio-
myopathy (Figure 4).31
To test the robustness of our predictive modeling, we
also performed a training-validation modeling exercise.
This approach is stricter in assessing the adequacy of a
predictive model because it evaluates its performance in a
totally different data set from the one with which it has been
developed. The model derived in the training set was similar
to the one obtained when all data where considered, al-
though understandably the two models were not exactly the
same. Importantly, four of the five predictors were retained,
and the magnitude of their effects was largely unchanged.
Past CHF was not selected in the training-validation ap-
proach, perhaps because of more limited data. Even a model
with four predictors, however, performed well on a com-
pletely different validation set and separated high- and
low-risk quartiles with about 4-fold differences in the odds
of death. In the absence of a good history on the extent of
past CHF, the four-predictor score may also be used with
quite satisfactory performance.
There are several limitations in this study. First, this was
a retrospective investigation. Nevertheless, the information
on preoperative risk factors was collected with highly stan-
dardized methods for the New York State database. Second,
a most important limitation, is that preoperative myocardial
viability, which has consistently been shown to be a strong
predictor of long-term mortality, was not routinely deter-
mined. However, Samady and coauthors32 have shown that
lack of improvement of ventricular function is associated
with a similar survival and similar improvement of angina
and heart failure as seen in patients with improved ventric-
ular function, suggesting that in patients with low EF meth-
ods for assessment of myocardial viability may underesti-
mate the potential for symptomatic and survival benefit
achieved by CABG. Importantly, our model needs to be
validated externally in data sets derived from other centers
and settings. The split-sample approach ensures that the
derived discriminatory ability is probably not inflated, but
no internal validation approach (split-sample, bootstrap-
ping, or other) can ensure satisfactory performance on dif-
ferent external data sets. For external applications, the co-
efficients of the HAVOC model may be shrunk (eg, by 0.78)
to get more accurate estimates of expected survival. Nev-
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should be used for general decision making on whether a
patient exceeds the threshold for CABG candidacy, rather
than for estimating the exact mortality risk. Finally, the
cause of death in these patients is not documented and was
not necessarily cardiac related, whereas survival in relation
to graft patency is unknown. However, for practical pur-
poses prediction of overall mortality is probably more im-
portant than prediction of cardiac deaths alone. Administra-
tive follow-up can be extremely useful, particularly when
the outcomes to be examined are limited to all-cause mor-
tality, which is less prone to error than administrative cod-
ing of medical diagnoses or procedures. However, there are
still limitations of this approach, including inability to
match patients and to confirm a patient’s status as alive.
In conclusion, and acknowledging these limitations, this
first multivariable predictive score of midterm and long-
term survival from a large patient database for many years
should be helpful in determining the optimal therapy for the
growing group of patients with ischemic cardiomyopathy.
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